Amplia Therapeutics Limited (ASX:ATX)

Market Cap	62.85M +86.2%
Revenue (ttm)	5.01M +46.8%
Net Income	-7.93M
EPS	-0.02
Shares Out	513.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	799,873
Average Volume	495,516
Open	0.1200
Previous Close	0.1225
Day's Range	0.1200 - 0.1300
52-Week Range	0.0490 - 0.4250
Beta	0.81
RSI	46.04
Earnings Date	Feb 26, 2026

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATX

Financial Performance

In fiscal year 2025, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2024.